Topics

Companies Related to "MAP to Provide Access to Crizanlizumab, for Sickle Cell Disease Patients" [Most Relevant Company Matches] RSS

04:20 EST 28th February 2020 | BioPortfolio

Here are the most relevant search results for "MAP to Provide Access to Crizanlizumab, for Sickle Cell Disease Patients" found in our extensive corporate database of over 50,000 company records.

Showing "Provide Access Crizanlizumab Sickle Cell Disease Patients" Companies 1–25 of 11,000+

Extremely Relevant

Imara, Inc.

Imara, Inc. is dedicated to developing novel therapeutics for patients with sickle cell disease and other hemoglobinopathies. Imara is currently developing IMR-687, a highly selective, potent small molecule inhibitor of PDE9, to treat patients with sickle cell disease. IMR-687 has been specifically designed to treat patients with sickle cell disease by bot...


Imara Inc.

Imara Inc., a Cydan Development company, is dedicated to developing novel therapeutics for patients with sickle cell disease. Imara is developing IMR-687, a highly selective, potent small molecule inhibitor of PDE9, to treat patients with sickle cell disease. The company was launched following an 18-month diligence and de-risking scientific collabor...

Sickle Cell Foundation of Tennessee

“Our mission is to provide social services, including health, education and life skills, to enhance the quality of life and self-sufficiency of individuals living with Sickle Cell,” said Thompson. “Everything we plan builds our capacity and extends our reach to serve more people. We must grow because there are people in pain who need our help.â€...


Relevant

Emmaus Life Sciences, Inc.

Emmaus Life Sciences is dedicated to the discovery, development and commercialization of innovative treatments and therapies for rare diseases. The Company’s research on sickle cell disease and sickle beta-0 thalassemia was initiated by Dr. Niihara at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center. The therapy has Orphan D...

National Stomp Out Sickle Cell Walk

The William E. Proudford Sickle Cell Fund

Angiogenix, Inc.

Angiogenix is a biopharmaceutical company developing therapeutic solutions for chronic vascular disease. We are a product-oriented company. Our products generally address the improvement of blood flow by improving vascular function. Within this framework, our products cover a broad range of types and indications, from novel combination drugs to a new proprietary drug for sickle cell disease. We al...

Vertex Pharmaceuticals (Europe) Limited

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has three approved medicines that treat the underlying cause of cystic fibrosis – a rare, life-threatening genetic disease — and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of...

Acceleron Pharma Inc. and Fulcrum Therapeutics

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s proprietary product engine identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. Fulcrum has advanced losmapimod to Phase 2 clinical develo...

INCELL Corp

INCELL was founded in 1993, by a UTHSCSA professor who wanted to continue her work in cell-based theraputics. Over the years Dr. Moyer has grown INCELL and made significant findings in cell-based theraputics. Our goal is to provide "translational" research to the clinic. We provide customized projects, looking at the needs of our customers. Currently our clinical applications are focused on cell-b...

BioMarin Pharmaceutical

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, focusing on product candidates that: * Address currently unmet medical needs * Suggest a clear-cut development profile * Provide an opportunity to be first-to-market The company's product portfolio is comprised of three approved products and multiple investigational product...

DeuteRx LLC

DeuteRx is pioneering ‘deuterium-enabled chiral switching’ (DECS), a revolutionary approach to improve racemic (a mixture of two mirror-image compounds or enantiomers) small molecule marketed drugs and drug candidates intended for patients across multiple therapeutic indications. Numerous drugs are still developed and marketed as racemic mixtures...

t2cure GmbH

t2cure is dedicated to the development of novel progenitor cell-based regenerative therapeutics to provide new treatment options to patients suffering from cardiac or peripheral vascular diseases like myocardial infarction or peripheral artery occlusive disease.

Vineti, Inc.

Vineti is the first commercial, configurable cloud-based platform to expand patient access to life-saving cell and gene therapies. Vineti was co-founded by GE and the Mayo Clinic to solve the key challenges patients, medical providers, biopharmaceutical companies and regulators face in the delivery and commercialization of individualized therapies. The Vin...

Opsis Therapeutics

Opsis Therapeutics is a company focused on discovering and developing new medicines to restore vision to patients suffering from retinal diseases. By combining recent innovations in induced pluripotent cell (iPSC) manufacturing, retinal cell differentiation, functional biomaterials, pre-clinical models of retinal disease, and cell therapeutic delivery tech...

Trucode Gene Repair

Trucode Gene Repair is advancing its novel triplex gene editing platform to potentially cure devastating genetic diseases, with initial focus on sickle cell disease and cystic fibrosis. The elegance of triplex gene editing lies in its ability to harness natural, high-fidelity DNA repair mechanisms, and its independence from the requirement for exogenous nucleases and viral vectors. Trucode is hea...

Celtor Biosystems A/S

CelTor is a product-based biotechnology company engaged in the discovery and development of novel drug compounds for the treatment of inflammatory disease using its proprietary CelBase™ Disease Models. These disease models replicate cell-to-cell interactions that are critical in the inflammation cascade.

HopeLab

HopeLab is a non-profit organization founded in 2001 by Board Chair Pam Omidyar. HopeLab combines rigorous research with innovative solutions to improve the health and quality of life of young people living with chronic illness. HopeLab applies a research-based, customer-focused development model to create products that address chronic illnesses in young people, including cancer, obesity, sic...

Brainstorm Cell Therapeutics

BrainStorm (OTC BB: BCLI) is a company that is developing stem cell technologies to provide treatments for currently incurable neurodegenerative diseases. The Company is focused on developing adult stem cells taken from the patient's own bone marrow to treat diseases such as Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease) and Multiple Sclerosis (MS). The adu...

Novocell, Inc

Novocell’s goal is to develop a renewable source of specialized cells that can be used to treat chronic cellular diseases. To achieve this goal, Novocell is uniquely positioned to exploit human stem cell engineered product opportunities using its proprietary cell encapsulation technology. Combined with Novocell's expertise in cell transplantation, these technologies will allow large numbers of p...

Regenacy Pharmaceuticals

Regenacy Pharmaceuticals, LLC is a clinical-stage biopharmaceutical company regenerating biological function by protein acetylation for the treatment peripheral neuropathies, cognitive disorders, hemoglobinopathies and oncology indications. The company’s selective inhibition technology provides superior safety profiles and potential enhanced efficacy ...

Selexys Pharmaceuticals Corporation

Selexys Pharmaceuticals Corporation (Selexys) is a privately held company that develops and commercializes therapeutics to treat inflammatory and thrombotic diseases. The company has completed research and is in preclinical development of two drug candidates, a monoclonal antibody and a glycosulfopeptide, that have broad application for the treatment of acute and chronic inflammatory disorders. Th...

Access Community Health Network

Access Community Health Network offers preventive services, medical care and consultation with specialists in nearly 60 community health center locations throughout Chicago, and suburban Cook and DuPage counties. Accredited by the Joint Commission, ACCESS health centers provide high-quality, affordable health care to more than 215,000 patients of all ages. Visit www.accesscommunityhealth.net and f...

Patients and Physicians for Rx Access

Patients and Physicians for Rx Access is a coalition consisting of individual patients, patient advocacy groups, pharmacists, physicians, pharmacies and healthcare organizations working to save patient access to compounded medications. The coalition formed to protect patients from the immediate threat from a growing number of pharmacy benefit managers and ...

Medinox, Inc

Medinox, Inc. is a San Diego-based pharmaceutical company that is developing new small molecule drugs to treat a wide variety of unmet medical needs including sepsis, arthritis & inflammation, diabetes and sickle cell anemia. The Company's research and clinical development programs fall into two broad categories: 1) nitric oxide neutralizers, and 2) novel prodrugs.


More From BioPortfolio on "MAP to Provide Access to Crizanlizumab, for Sickle Cell Disease Patients"

Quick Search

Corporate Database Quicklinks